News - FGFR2 expression

1year

Establishing a new human lung squamous cell carcinoma cell line, OMUL-1, expressing insulin-like growth factor 1 receptor and programmed cell death ligand 1. (PubMed, Thorac Cancer)

We developed a novel new squamous cell lung carcinoma cell line, OMUL-1, that expresses IGF1R and PD-L1.

1 year ago

Preclinical • Journal • PD(L)-1 Biomarker • IO biomarker

EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • MET (MET proto-oncogene, receptor tyrosine kinase) • FGFR2 (Fibroblast growth factor receptor 2) • FGFR3 (Fibroblast growth factor receptor 3) • FGFR1 (Fibroblast growth factor receptor 1) • ERBB3 (V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3) • PDGFRA (Platelet Derived Growth Factor Receptor Alpha) • PDGFRB (Platelet Derived Growth Factor Receptor Beta) • FGFR4 (Fibroblast growth factor receptor 4) • IGF1R (Insulin-like growth factor 1 receptor) • ERBB4 (erb-b2 receptor tyrosine kinase 4) • FLT4 (Fms-related tyrosine kinase 4) • NKX2-1 (NK2 Homeobox 1) • TP63 (Tumor protein 63)

PD-L1 expression • FGFR1 expression • IGF1R expression • FGFR2 expression • FGFR2b expression • FGFR3 expression • TTF1 negative

picropodophyllin (AXL1717)

1year

Advanced Intrahepatic Cholangiocarcinoma (iCCA): Investigating Co-Molecular Alterations (AIOM 2024)

The FGFR and IDH-1 pathways are the primary targets for therapy, with FGFR-2 and IDH-1 inhibitors, such as Pemigatinib and Ivosidenib respectively, already available on the market. This prospective study validates the prevalence of mutations documented in the literature and underscores the significance of NGS in presenting supplementary therapeutic avenues. Moreover, we demonstrated the role of other potential targets co-expressed with FGFR2 or IDH1 which could represent a crucial opportunity for novel combinations or sequences therapies.

1 year ago

BRCA Biomarker • Metastases

HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • TP53 (Tumor protein P53) • BRCA2 (Breast cancer 2, early onset) • FGFR2 (Fibroblast growth factor receptor 2) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • ARID1A (AT-rich interaction domain 1A) • MTAP (Methylthioadenosine Phosphorylase) • BAP1 (BRCA1 Associated Protein 1) • CDKN2B (Cyclin Dependent Kinase Inhibitor 2B) • NTRK (Neurotrophic receptor tyrosine kinase) • CA 19-9 (Cancer antigen 19-9)

TP53 mutation • KRAS mutation • IDH1 mutation • FGFR2 mutation • FGFR2 fusion • CDKN2A mutation • BAP1 mutation • FGFR2 expression • FGFR2b expression

FoundationOne® CDx

Pemazyre (pemigatinib) • Tibsovo (ivosidenib)

1year

Novel deoxyhypusine synthase (DHPS) inhibitors target hypusination-induced vasculogenic mimicry (VM) against malignant melanoma. (PubMed, Pharmacol Res)

Pharmacokinetic evaluations demonstrated 7k's favorable properties, and xenograft models evidenced its notable anti-melanoma efficacy, achieving a TGI of 73%. These results highlighted DHPS as key in melanoma VM formation and confirmed 7k's potential as a novel anti-melanoma agent.

1 year ago

Journal

FGFR2 (Fibroblast growth factor receptor 2) • KIT (KIT proto-oncogene, receptor tyrosine kinase)

KIT expression • FGFR2 expression

1year

Genomic and transcriptomic profiling of pre- and postneoadjuvant chemotherapy triple negative breast cancer tumors. (PubMed, Cancer Sci)

To advance our understanding of the role of breast cancer driver genes' mutational status with pathological complete response (pCR; ypT0/isypN0) prediction and to identify distinct gene sets for MTIs like eribulin and paclitaxel, we carried out targeted genomic (n = 50) and whole transcriptomic profiling (n = 64) of TNBC tumor samples from the Japan Breast Cancer Research Group 22 (JBCRG-22) clinical trial. Differential enrichment analysis of the HRD-high group posttreatment tumors revealed significant correlation (p = 0.006) of the glycan degradation pathway. FGFR2 expression and the differentially enriched pathways play a role in the response and resistance to MTIs containing carboplatin treatment in TNBC patients.

1 year ago

Journal • BRCA Biomarker

TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • BRCA2 (Breast cancer 2, early onset) • FGFR2 (Fibroblast growth factor receptor 2) • PTEN (Phosphatase and tensin homolog) • HRD (Homologous Recombination Deficiency) • HRAS (Harvey rat sarcoma viral oncogene homolog) • BRCA (Breast cancer early onset)

TP53 mutation • BRCA2 mutation • PIK3CA mutation • HRD • PTEN mutation • FGFR2 mutation • HRAS mutation • BRCA mutation • FGFR2 expression • FGFR2b expression • High HRD score

carboplatin • paclitaxel • Halaven (eribulin mesylate)

1year

Developing New Peptides and Peptide-Drug Conjugates for Targeting the FGFR2 Receptor-Expressing Tumor Cells and 3D Spheroids. (PubMed, Biomimetics (Basel))

Results demonstrated that Trimer-pep conjugated with DOX showed the highest permeation, while the ACSAG conjugate also demonstrated reasonable permeation of the drug. These results indicate that these peptides may be further explored and potentially utilized to create drug conjugates for targeting tumor cells expressing FGFR2 for developing therapeutics.

1 year ago

Journal • Tumor cell

FGFR2 (Fibroblast growth factor receptor 2)

FGFR2 fusion • FGFR2 expression • FGFR2b expression

1year

Targeted and combination immunotherapies using biologics for gastric cancer: the state-of-the-art. (PubMed, Expert Opin Biol Ther)

FDA approval of zolbetuximab's, an anti-CLDN18.2monoclonal antibody, is expected soon. Additionally, bemarituzumab, ananti-FGFR2b monoclonal antibody, has shown improvements in combination withchemotherapy in those with HER2 negative GAC with FGFR2 overexpression...Lastly, TROP-2 has emergedas an exciting solid tumor target and study is expected in GAC. All three ofthese therapeutic targets have seen an abundance of drug development in recentyears, and we anticipate newer targeted agents driving therapeutic decisions inGAC in the coming years.

1 year ago

Review • Journal • IO biomarker

HER-2 (Human epidermal growth factor receptor 2) • MSI (Microsatellite instability) • FGFR2 (Fibroblast growth factor receptor 2) • CLDN18 (Claudin 18)

MSI-H/dMMR • HER-2 overexpression • HER-2 negative • FGFR2 overexpression • FGFR2 expression

Keytruda (pembrolizumab) • Opdivo (nivolumab) • Yervoy (ipilimumab) • Vyloy (zolbetuximab-clzb) • bemarituzumab (AMG 552)

over1year

FGFR2-triggered autophagy and activation of Nrf-2 reduce breast cancer cell response to anti-ER drugs. (PubMed, Cell Mol Biol Lett)

This study revealed the unknown role of FGFR2 signalling in activation of autophagy and regulation of the p62/Keap1/Nrf-2 interdependence, which has a negative impact on the response of ER+ BCa cells to anti-ER therapies. The data from in silico analyses suggest that expression of Nrf-2 could act as a marker indicating potential benefits of implementation of anti-FGFR therapy in patients with ER+ BCa, in particular, when used in combination with anti-ER drugs.

over 1 year ago

Journal

ER (Estrogen receptor) • FGFR2 (Fibroblast growth factor receptor 2) • KEAP1 (Kelch Like ECH Associated Protein 1) • NFE2L2 (Nuclear Factor, Erythroid 2 Like 2) • SQSTM1 (Sequestosome 1)

ER positive • FGFR mutation • FGFR2 expression • FGFR2b expression • NFE2L2 expression

over1year

Cancer-associated fibroblasts secrete FGF5 to inhibit ferroptosis to decrease cisplatin sensitivity in nasopharyngeal carcinoma through binding to FGFR2. (PubMed, Cell Death Dis)

In conclusion, CAFs inhibited ferroptosis to decrease DDP sensitivity in NPC through secreting FGF5 and activating downstream FGFR2/Nrf2 signaling. The therapeutic strategy targeting FGF5/FGFR2 axis from CAFs might augment DDP sensitivity, thus decreasing the side effects of DDP in NPC treatment.

over 1 year ago

Journal

FGFR2 (Fibroblast growth factor receptor 2)

FGFR2 overexpression • FGFR2 expression

cisplatin

over1year

Expression of fibroblast growth factor receptor 2 (FGFR2) in combined hepatocellular-cholangiocarcinoma and intrahepatic cholangiocarcinoma: clinicopathological study. (PubMed, Virchows Arch)

FGFR2::BICC fusion was detected in a case of cHCC-CCAs. FGFR2 genetic alterations may be prevalent in cHCC-CCAs as well as small duct-type iCCAs, which suggest cHCC-CCAs may also be a possible therapeutic target of FGFR2 inhibitors.

over 1 year ago

Journal

FGFR2 (Fibroblast growth factor receptor 2) • ARID1A (AT-rich interaction domain 1A) • BAP1 (BRCA1 Associated Protein 1) • BICC1 (BicC Family RNA Binding Protein 1) • NES (Nestin)

FGFR2 fusion • FGFR2 expression • FGFR2b expression • NES expression

over1year

Defective FGFR2 Signaling in the Small Airway Basal Progenitor Cells in COPD (clinicaltrials.gov)

P=N/A, N=120, Active, not recruiting, Weill Medical College of Cornell University | Trial completion date: Dec 2023 --> Dec 2025 | Trial primary completion date: Dec 2023 --> Dec 2025

over 1 year ago

Trial completion date • Trial primary completion date

FGFR2 (Fibroblast growth factor receptor 2)

FGFR2 expression • FGFR2b expression

over1year

FGFR2 and miR-889-3p expression in oral cancer is associated with cervical lymph node metastasis. (PubMed, Oral Dis)

Decreased expression of miR-889-3p in OSCC tumours suggests that miR-889-3p functions as a tumour suppressor gene. Overexpression of FGFR2 further proves the role of miR-889-3p in the regulation of the FGFR2 pathway. This was further confirmed by showing differences in miR-889-3p expression in positive and negative LNM cases.

over 1 year ago

Journal

FGFR2 (Fibroblast growth factor receptor 2)

FGFR2 overexpression • FGFR2 expression • FGFR2b expression

almost2years

Activated FGFR2 signalling as a biomarker for selection of intrahepatic cholangiocarcinoma patients candidate to FGFR targeted therapies. (PubMed, Sci Rep)

This last finding entails that also this setting of patients could benefit from FGFR targeted therapies, widening indication of these drugs for iCCA patients beyond current approval. Future clinical studies are therefore encouraged to confirm this hypothesis.

almost 2 years ago

Journal

FGFR2 (Fibroblast growth factor receptor 2) • FGF10 (Fibroblast Growth Factor 10)

FGFR2 mutation • FGFR2 expression • FGFR2b expression • FGFR2 C382R • FGFR2 F276C • FGFR2 Y375C • FGFR wild-type • FGFR2 wild-type